Integra LifeSciences Holdings Corporation — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual Form 10-K; fourth-quarter data are included in the annual results and unaudited quarterly information.
Business context
Integra is a medical technology company operating in two reportable segments: Codman Specialty Surgical, focused on neurosurgery, neuro-critical care, instruments and related devices; and Orthopedics and Tissue Technologies, focused on regenerative tissue, wound care, surgical reconstruction and orthopedic products. Revenue is generated through direct sales forces, distributors, wholesalers and strategic partners globally.
The business was materially affected by COVID-19-related procedure postponements, hospital resource reallocations and deferred capital spending, particularly during the first half of 2020. Management reported sequential recovery in the second half of the year.
Financial performance and key metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $1,371.9 million | $1,517.6 million | Down 9.6% |
| Gross profit | $851.0 million | $952.9 million | Down $101.8 million |
| Gross margin | 62.0% | 62.8% | Down 80 bps |
| Operating income | $151.4 million | $93.8 million | Up $57.6 million |
| Income before taxes | $93.5 million | $60.1 million | Up $33.4 million |
| Net income | $133.9 million | $50.2 million | Up $83.7 million |
| Diluted EPS | $1.57 | $0.58 | Up $0.99 |
| Cash flow from operations | $203.8 million | $231.4 million | Down $27.6 million |
| Capital expenditures | $38.9 million | $69.5 million | Down $30.6 million |
Quarterly pattern: 2020 revenue was $354.3 million in the first quarter, $258.7 million in the second quarter, $370.2 million in the third quarter and $388.6 million in the fourth quarter. Fourth-quarter net income was $92.7 million, compared with a $0.4 million loss in the second quarter.
- Codman Specialty Surgical revenue was $894.8 million, down 10.2% from 2019.
- Orthopedics and Tissue Technologies revenue was $477.0 million, down 8.5%.
- Domestic revenue was $972.0 million, down 9.8%; international revenue was $399.9 million, down 9.2%.
- Operating expenses declined 18.6% to $699.7 million, reflecting temporary compensation reductions, hiring restrictions, lower commissions, reduced discretionary spending and lower acquisition-related charges.
- Reported net income benefited from a $59.2 million deferred tax benefit related to an intra-entity transfer of intellectual property to Switzerland. Excluding this benefit and the prior-year $64.9 million Rebound in-process research and development charge, management stated that 2020 net income declined by $40.4 million versus 2019.
Liquidity, debt and capital resources
- Cash and cash equivalents increased to $470.2 million at December 31, 2020 from $198.9 million at year-end 2019.
- Working capital increased to $836.2 million from $526.9 million.
- Total consolidated external debt was approximately $1.1 billion. Debt included $975.0 million outstanding under the Senior Credit Facility, $112.5 million under the securitization facility and $575.0 million principal amount of 0.5% convertible notes due 2025, before accounting discounts.
- The Senior Credit Facility had approximately $325.0 million available for future borrowings at year-end. The company was in compliance with its debt covenants and expected to remain compliant over the following year.
- Operating cash flow remained positive despite lower earnings and increased inventory safety stock. Financing cash flow was $121.6 million, primarily reflecting convertible-note proceeds and debt activity, partially offset by debt repayments, financing costs and $100.0 million of share repurchases.
- The company has not paid cash dividends and does not currently report an off-balance-sheet financing arrangement material to its financial condition.
Material changes versus the prior comparable period
- COVID-19 reduced surgical procedure volumes and hospital capital spending, causing an 18% revenue decline in the first half of 2020. Second-half revenue declined only 2% year over year and increased 24% versus the first half.
- Gross margin declined modestly due primarily to pandemic-related disruption and manufacturing transition costs, partly offset by favorable product mix.
- Operating income increased despite lower revenue because 2019 included substantial acquisition-related and Rebound IPR&D charges, while 2020 benefited from expense controls.
- Interest expense increased to $71.6 million from $54.0 million, primarily due to non-cash interest from the convertible notes and debt refinancing activity.
- The company issued $575.0 million of convertible senior notes in February 2020 and completed a $100.0 million share repurchase, including a $92.4 million accelerated share repurchase.
- Extremity Orthopedics was classified as held for sale at year-end and was sold to Smith & Nephew on January 4, 2021 for $240.0 million in cash. Integra concurrently paid $41.5 million to terminate a related licensing arrangement.
- Integra acquired ACell on January 20, 2021 for $300.0 million, with potential additional payments of up to $100.0 million tied to revenue-based milestones.
Guidance, outlook, risks and unusual items
Management did not provide a detailed full-year revenue or earnings forecast in the filing. It estimated a 2021 worldwide effective tax rate of approximately 20.0% and expected annual amortization expense of approximately $63.8 million in 2021, excluding amortization associated with the ACell acquisition and future acquired in-process research and development.
Management viewed the underlying neurosurgery and regenerative medicine markets as attractive over the long term, while noting that procedure recovery would vary by geography, product line and future COVID-19 surges or variants. Cost controls were eased during the second half of 2020 as revenue improved, and the company continued investing in research, development, clinical programs and growth initiatives.
- COVID-19: Further procedure cancellations, hospital financial strain, supply-chain disruption, facility restrictions and reduced capital spending could materially affect revenue, cash flow and liquidity.
- Regulatory exposure: The FDA maintained its position that certain morselized amniotic tissue products may require regulation beyond Section 361 HCT/P requirements. Related 2020 revenue was less than 1% of consolidated revenue, but enforcement could affect sales.
- FDA quality matters: A 2019 warning letter concerning quality-system issues at the TEI Boston facility remained unresolved. Products manufactured there represented approximately 4.5% of 2020 consolidated revenue. The company reported progress and no current restriction on manufacturing or shipping, but further regulatory action remains possible.
- Leverage and interest rates: Debt service, variable-rate borrowings, LIBOR transition and covenant requirements could constrain financial flexibility. The company uses interest-rate swaps to hedge a portion of its exposure.
- Animal- and human-tissue products: Approximately 39.3% of 2020 revenue came from products containing bovine-derived material, creating sourcing, regulatory and market-acceptance risks.
- Acquisitions and divestitures: Integration costs, contingent consideration, impairment risk and the execution of the ACell acquisition and Extremity Orthopedics divestiture could affect future results.
- Unusual items: 2020 included $89.0 million of identified special charges, including debt-related charges, structural optimization, EU medical device regulation, discontinued product lines and COVID-19 costs. The $59.2 million tax benefit was a significant non-recurring or unusual contributor to reported earnings.
Most important facts for investors to verify
- Whether procedure volumes and hospital capital spending fully recover after COVID-19 disruptions, particularly in Codman capital equipment and instruments.
- The sustainability of reported profitability excluding the $59.2 million intellectual-property-related tax benefit and other special charges.
- Post-closing financial effects, integration progress and contingent milestone obligations related to the $300.0 million ACell acquisition.
- Use of the $240.0 million Extremity Orthopedics sale proceeds and the effect of the divestiture on revenue mix, margins and growth.
- Resolution and potential consequences of the TEI Boston FDA warning letter and the FDA’s position on morselized amniotic tissue products.
- Debt maturities, covenant headroom, the $112.5 million securitization facility due December 2021 and the $575.0 million convertible notes due August 2025.
- Inventory valuation, goodwill and intangible-asset impairment assumptions given pandemic-related uncertainty and the company’s substantial intangible asset balances.